美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inspire Corporate Bond ETF

24.25

+0.07000.29%

成交量：3.68萬

成交額：89.17萬

市值：4.80億

市盈率：- -

高：24.28

開：24.19

低：24.17

收：24.18

52周最高：24.85

52周最低：22.84

股本：1,980.00萬

流通股本：1,980.00萬

量比：0.56

換手率：0.19%

股息：1.01

股息率：4.16%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

釋放pipeline in a drug潛力 NLRP3能否催生下一個「藥王」?

智通财经网

Vivosim Labs, Inc.盤中異動大幅下跌8.35%

60億美元豪賭見效！武田自免口服新藥針對中重度斑塊狀銀屑病3期數據積極，擬明年向FDA提交上市申請

中信證券：新老管線數據讀出頻現 MNC加速IBD領域佈局

顯著降低克羅恩病用藥負擔，利生奇珠單抗納入新版國家醫保目錄

Vivosim Labs, Inc.盤中異動早盤股價大漲7.31%

Vivosim Labs, Inc.盤中異動下午盤股價大漲5.29%

Spyre Therapeutics宣佈授予員工股票期權激勵獎勵

羅氏(RHHBY.US)4億美元加碼IBD領域開發臨牀前口服小分子

恒瑞醫藥的新爆點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IBD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.25,"timestamp":1770757200000,"preClose":24.18,"halted":0,"volume":36828,"delay":0,"changeRate":0.0028949545078577454,"floatShares":19800000,"shares":19800000,"eps":0,"marketStatus":"盤前交易","change":0.07,"latestTime":"02-11 07:50:37 EST","open":24.19,"high":24.28,"low":24.1711,"amount":891739.268547,"amplitude":0.004504,"askPrice":29.57,"askSize":100,"bidPrice":19.44,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1770820200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.25,"sharesOutstanding":19800000,"nav":24.15,"aum":478218499.76,"dividendRate":0.041625,"bidAskSpread":0.002129,"postHourTrading":{"tag":"盘后","latestPrice":24.25,"preClose":24.25,"latestTime":"16:10 EST","volume":12,"amount":291,"timestamp":1770757804822,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5626650054316973},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":19800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5626650054316973,"shares":19800000,"dividePrice":1.0094,"high":24.28,"amplitude":0.004504,"preClose":24.18,"low":24.1711,"week52Low":22.84,"pbRate":"--","week52High":24.85,"institutionHeld":0,"latestPrice":24.25,"eps":0,"divideRate":0.041625,"volume":36828,"delay":0,"ttmEps":0,"open":24.19,"prevYearClose":24.2,"prevWeekClose":24.25,"prevMonthClose":24.15,"prevQuarterClose":24.2,"fiveDayClose":24.04,"twentyDayClose":24.09,"sixtyDayClose":24.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2026-01-27","symbol":"IBD","amount":0.0592,"announcedDate":"2026-01-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-27","defaultRemindTime":1769524200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-27","currency":"USD","dateTimestamp":1769490000000,"payDate":"2026-02-02"},{"date":"2025-12-17","symbol":"IBD","amount":0.121,"announcedDate":"2025-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-17","defaultRemindTime":1765981800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-17","currency":"USD","dateTimestamp":1765947600000,"payDate":"2025-12-24"},{"date":"2025-11-21","symbol":"IBD","amount":0.0729,"announcedDate":"2025-11-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-21","defaultRemindTime":1763735400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-26","payableDate":"2025-11-21","currency":"USD","dateTimestamp":1763701200000,"payDate":"2025-11-26"},{"date":"2025-10-28","symbol":"IBD","amount":0.0824,"announcedDate":"2025-10-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-28","defaultRemindTime":1761658200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-03","payableDate":"2025-10-28","currency":"USD","dateTimestamp":1761624000000,"payDate":"2025-11-03"},{"date":"2025-09-26","symbol":"IBD","amount":0.0899,"announcedDate":"2025-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-26","defaultRemindTime":1758893400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-01","payableDate":"2025-09-26","currency":"USD","dateTimestamp":1758859200000,"payDate":"2025-10-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609432256","title":"釋放pipeline in a drug潛力 NLRP3能否催生下一個「藥王」?","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432256","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609432256?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 16:35","pubTimestamp":1770280559,"startTime":"0","endTime":"0","summary":"近期，英硅智能(03696)宣布提名靶向NLRP3的外周限制性抑制剂ISM5059，该候选药物具有新颖母核，由英硅智能自有Pharma.AI平台驱动设计。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1169590202.USD","BK4135","BK4132","CNS","PD","AD","LU1169589451.USD","IBD","BK4023","BBB"],"gpt_icon":0},{"id":"2602122803","title":"Vivosim Labs, Inc.盤中異動 大幅下跌8.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602122803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602122803?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 01:55","pubTimestamp":1767894943,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日01时55分，Vivosim Labs, Inc.股票出现异动，股价大幅下挫8.35%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.93%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109015545a4acf44f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","VIVS"],"gpt_icon":0},{"id":"2592755154","title":"60億美元豪賭見效！武田自免口服新藥針對中重度斑塊狀銀屑病3期數據積極，擬明年向FDA提交上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2592755154","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592755154?lang=zh_tw&edition=fundamental","pubTime":"2025-12-19 16:36","pubTimestamp":1766133370,"startTime":"0","endTime":"0","summary":"近日，武田宣布其针对中重度斑块状银屑病成人患者的新一代、高选择性口服酪氨酸激酶2抑制剂Zasocitinib在两项关键性3期、随机、多中心、双盲、安慰剂与活性对照研究中取得积极的主要结果。据悉，武田制药计划在即将举行的医学会议上公布研究数据，并计划自2026财年向美国食品药品监督管理局及其他监管机构递交新药上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766128980838994392","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBD","BMS"],"gpt_icon":0},{"id":"2590550876","title":"中信證券：新老管線數據讀出頻現 MNC加速IBD領域佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590550876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590550876?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 09:34","pubTimestamp":1765416866,"startTime":"0","endTime":"0","summary":"MNC加速IBD领域布局，中国创新药企业在差异化赛道崭露头角。MNC加速IBD领域布局，中国创新药企业在差异化赛道崭露头角作为自身免疫疾病领域中，患者人数众多且当前一年维持期疗效仍仅有30%-50%临床缓解率的适应症，IBD吸引了众多MNC布局。根据过往交易规模以及MNC对产品峰值的预期，该行预计一项临床阶段的优质IBD资产的交易对价在20亿美金以上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1655091616.SGD","06030","BK1516","BK1147","LU2148510915.USD","BK1521","LU0405327494.USD","LU1328615791.USD","LU1997244956.HKD","LU2289578879.USD","LU0405327148.USD","LU1064131003.USD","LU1064130708.USD","LU1997245094.SGD","BK0188","BK1564","LU1997245177.USD","BK0196","LU1255011170.USD","IBD","BK0276","LU1720050803.USD","BK0183","BK0028","600030","BK0012","LU2495084118.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2589216380","title":"顯著降低克羅恩病用藥負擔，利生奇珠單抗納入新版國家醫保目錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2589216380","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589216380?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 15:56","pubTimestamp":1765180571,"startTime":"0","endTime":"0","summary":"12月7日，《国家基本医疗保险、工伤保险和生育保险药品目录（2025年版）》（以下简称“医保目录”）正式公布，全球生物医药公司艾伯维旗下靶向创新药物利生奇珠单抗注射液（喜开悦?）位列其中。该药物在获批上市当年即被纳入医保，充分体现了其临床价值与国家医保政策对创新疗法的支持力度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585275052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NICE","BK4543","BK4023","IE00BFMHRM44.USD","IBD","BK4566"],"gpt_icon":0},{"id":"2587075284","title":"Vivosim Labs, Inc.盤中異動 早盤股價大漲7.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2587075284","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587075284?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 22:33","pubTimestamp":1764340392,"startTime":"0","endTime":"0","summary":"北京时间2025年11月28日22时33分，Vivosim Labs, Inc.股票出现波动，股价大幅上涨7.31%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体跌幅为0.19%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251128223312a4c0a7f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","VIVS"],"gpt_icon":0},{"id":"2582329246","title":"Vivosim Labs, Inc.盤中異動 下午盤股價大漲5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582329246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582329246?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 03:13","pubTimestamp":1762888437,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日03时13分，Vivosim Labs, Inc.股票出现异动，股价快速拉升5.29%。Vivosim Labs, Inc.股票所在的生物技术行业中，整体涨幅为1.47%。Vivosim Labs, Inc.公司简介：VivoSim Labs Inc前身为Organovo Holdings Inc，是一家生物技术公司，专注于开发FXR314治疗炎症性肠病，包括溃疡性结肠炎，基于三维人体组织的临床前景证明以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111203135797630a06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111203135797630a06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VIVS","IBD"],"gpt_icon":0},{"id":"1195222682","title":"Spyre Therapeutics宣佈授予員工股票期權激勵獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=1195222682","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195222682?lang=zh_tw&edition=fundamental","pubTime":"2025-10-04 04:08","pubTimestamp":1759522131,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2025年10月3日——临床阶段生物技术公司Spyre Therapeutics, Inc.今日宣布，公司独立董事会薪酬委员会批准向三名非执行员工授予总计42,500股普通股的股票期权，作为根据经修订的《Spyre Therapeutics, Inc. 2018年股权激励计划》项下的股权激励奖励。Spyre Therapeutics是一家临床阶段生物技术公司，致力于通过结合一流的抗体工程、剂量优化和合理的治疗组合，开发下一代炎症性肠病和其他免疫介导疾病产品。Spyre的产品管线包括针对α4β7、TL1A和IL-23的研究性延长半衰期抗体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4539","BK4139","BK4007","NQmain","SYRE","LENZ"],"gpt_icon":0},{"id":"2564007528","title":"羅氏(RHHBY.US)4億美元加碼IBD領域 開發臨牀前口服小分子","url":"https://stock-news.laohu8.com/highlight/detail?id=2564007528","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564007528?lang=zh_tw&edition=fundamental","pubTime":"2025-09-02 21:15","pubTimestamp":1756818907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团成员基因泰克达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病的临床前口服小分子项目。根据协议条款，OMass将获得2000万美元的首付款，此外还有可能获得超过4亿美元的潜在临床前、开发、商业和净销售额里程碑付款。在此合作下，OMass将主导该项目的初步临床前开发，直至候选化合物选定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBD","03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2560920343","title":"恒瑞醫藥的新爆點","url":"https://stock-news.laohu8.com/highlight/detail?id=2560920343","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560920343?lang=zh_tw&edition=fundamental","pubTime":"2025-08-17 07:31","pubTimestamp":1755387091,"startTime":"0","endTime":"0","summary":"近期，恒瑞医药又拿下一笔BD大单：将PDE3/4抑制剂HRS-9821的海外权益以及11个创新项目的独家选择权授权给葛兰素史克，将有望获得潜在总交易额125亿美元。这一利好消息，让恒瑞医药A股涨停，总市值成功突破4000亿元大关，H股的总市值更是一度超过5600亿港元。此次BD合作，再次验证了恒瑞在免疫和呼吸系统疾病领域的研发实力。恒瑞这两款重磅新药若想突围而出，面临着不小的压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817073528a48ceda7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250817073528a48ceda7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK","BK4007","BK4532","LU1829250122.USD","BK4585","BK4588","IBD","GSK.UK"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}